Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback